文献速递胸部肿瘤

MET外显子14跳跃突变肺癌的一线免疫治疗及TP53突变的相关性

First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.
PubMed 文献 · Eur J Cancer · 2024-01-17

该研究分析了2016至2022年间德国10个中心110例接受一线化疗和/或免疫治疗的MET外显子14跳跃突变非小细胞肺癌患者。结果显示化疗联合免疫治疗优于单纯化疗,免疫单药治疗也有效,尤其在TP53突变患者中,且不依赖PD-L1表达,但从不吸烟者原发进展风险更高。

要点

  • 化疗联合免疫治疗较单纯化疗延长中位无进展生存期(6 vs 2.5个月,p=0.004)。
  • 免疫单药治疗的总生存期和缓解持续时间与化疗联合免疫治疗相当。
  • TP53突变患者在多变量分析中总生存期更长(HR=0.54,p=0.034)。

核心结论

  • 化疗联合免疫治疗优于单纯化疗,免疫单药治疗对MET外显子14跳跃突变非小细胞肺癌也有效,尤其在TP53突变存在时且不依赖PD-L1表达,但从不吸烟者原发进展风险更高。

研究设计与样本

  • 研究分析了2016至2022年间德国10个中心连续纳入的110例接受一线化疗和/或免疫治疗的MET外显子14跳跃突变非小细胞肺癌患者。

主要发现

  • 化疗联合免疫治疗组35/110例(32%),免疫单药治疗组43/110例(39%),化疗组32/110例(29%)。
  • 与化疗相比,化疗联合免疫治疗的中位无进展生存期更长(6 vs 2.5个月,p=0.004),客观缓解率更高(49% vs 28%,p=0.086),总生存期数值上更长(16 vs 10个月,p=0.240)。
  • 免疫单药治疗与化疗联合免疫治疗相比,总生存期(14 vs 16个月)和缓解持续时间(26 vs 22个月)相当。
  • 免疫单药治疗组原发进展性疾病较化疗联合免疫治疗组更常见(13/43 vs 3/35,p=0.018),尤其在从不吸烟者中(p=0.041)。
  • TP53突变肿瘤较野生型肿瘤客观缓解率数值上更高(56% vs 32%,p=0.088),无进展生存期数值上更长(6 vs 3个月,p=0.160),多变量分析中总生存期更长(HR=0.54,p=0.034)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy of checkpoint inhibitors for non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METΔ14ex) remains controversial. MATERIALS AND METHODS: 110 consecutive METΔ14ex NSCLC patients receiving first-line chemotherapy (CHT) and/or immunotherapy (IO) in 10 German centers between 2016-2022 were analyzed. RESULTS: Combined CHT-IO was given to 35/110 (32%) patients, IO alone to 43/110 (39%), and CHT to 32/110 (29%) upfront. Compared to CHT, CHT-IO showed longer progression-free survival (median PFS 6 vs. 2.5 months, p = 0.004), more objective responses (ORR 49% vs. 28%, p = 0.086) and numerically longer overall survival (OS 16 vs. 10 months, p = 0.240). For IO monotherapy, OS (14 vs. 16 months) and duration of response (26 vs. 22 months) were comparable to those of CHT-IO. Primary progressive disease (PD) was more frequent with IO compared to CHT-IO (13/43 vs. 3/35, p = 0.018), particularly for never-smokers (p = 0.041). Higher PD-L1 TPS were not associated with better IO outcomes, but TP53 mutated tumors showed numerically improved ORR (56% vs. 32%, p = 0.088) and PFS (6 vs. 3 months, p = 0.160), as well as longer OS in multivariable analysis (HR=0.54, p = 0.034) compared to their wild-type counterparts. Any second-line treatment was administered to 35/75 (47%) patients, with longer survival for capmatinib or tepotinib compared to crizotinib (PFS 10 vs. 3 months, p = 0.013; OS 16 vs. 13 months, p = 0.270). CONCLUSION: CHT-IO is superior to CHT, and IO alone also effective for METΔ14ex NSCLC, especially in the presence of TP53 mutations and independent of PD-L1 expression, but never-smokers are at higher risk of primary PD.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Blasi M, Kuon J, Lüders H, et al. First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations. Eur J Cancer. 2024. PMID: 38271745. doi:10.1016/j.ejca.2024.113556

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。